Bruker reorganizes reportable segments, moving Daltonics into BIOS
Bruker (BRKR) moves the Daltonics and Optics divisions into a new BSI BIOS segment and creates a separate BMID segment, effective July 1. Consolidated results are unchanged.
Key takeaways
- Bruker (BRKR) reorganized its reportable segments effective July 1, 2026, creating BSI BIOS and BSI Microbiology and Infection Diagnostics (BMID) segments. Recast segment figures for 2024 through 2026 periods were provided. Consolidated results, financial position and cash flows are unchanged.
Bruker (BRKR) reorganized its reportable segments effective July 1 to streamline its structure and sharpen decision making, accountability and customer focus.
Shares rose 2.0% at 9:39 a.m. ET, from a $58.06 close.
BSI BIOS now brings together the BioSpin, SciY, Chemspeed Technologies (CST), Daltonics and Optics divisions, along with the Mimetas division. BioSpin absorbs the former Magnetic Resonance Spectroscopy, Preclinical Imaging, Biopharma and Applied Services, and Services and Lifecycle Support divisions.
BSI Microbiology and Infection Diagnostics (BMID) is a new segment made up of the Microbiology, Molecular Diagnostics and Biomedical Systems divisions, previously part of BSI CALID. BSI NANO and Bruker Energy & Supercon Technologies (BEST) keep their existing segment structure.
The Mimetas division was formed in the third quarter after Bruker acquired a majority interest in Mimetas B.V.
Recast segment figures cover fiscal 2024 and 2025, and quarterly and year-to-date periods in 2025 and 2026, under the new structure. For fiscal 2025, recast BIOS revenue was $1.58 billion, against $878.8 million for BioSpin under the old structure. BMID revenue was $508.9 million.
The realignment leaves consolidated results, financial position and cash flows unchanged.